FDA 483 - Teva Womens Health, LLC - January 26, 2018
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Teva Womens Health Inc. in Cincinnati, OH, a drug manufacturer, revealed significant deficiencies across multiple areas. Observations included a lack of quality control unit responsibility regarding product design and complaint handling, incomplete laboratory records for HPLC data, unsanitary conditions in the pharmacy sampling area, and non-adherence to written procedures for storing packaging and labeling materials. These findings indicate a need for improved quality system oversight and operational compliance.
ID · 6cb28d31-bd1d-49c3-a0e4-024bdce8c666